Joel Lebowitz Net Worth

The estimated Net Worth of Joel Lebowitz is at least $79.7 mil dollars as of 1 September 2021. Mr. Lebowitz owns over 5,574 units of Schrodinger stock worth over $79,727 and over the last 5 years he sold SDGR stock worth over $0. In addition, he makes $0 as Executive Vice President e Chief Financial Officer at Schrodinger.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lebowitz SDGR stock SEC Form 4 insiders trading

Joel has made over 12 trades of the Schrodinger stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,574 units of SDGR stock worth $24,191 on 1 September 2021.

The largest trade he's ever made was exercising 117,051 units of Schrodinger stock on 19 August 2020 worth over $508,001. On average, Joel trades about 14,022 units every 27 days since 2020. As of 1 September 2021 he still owns at least 3,874 units of Schrodinger stock.

You can see the complete history of Mr. Lebowitz stock trades at the bottom of the page.

Joel Lebowitz biography

Joel A. Lebowitz serves as Executive Vice President, Chief Financial Officer of the Company. Mr. Lebowitz previously spent 26 years at Merck, a pharmaceutical company, where he served as global finance lead, project management from September 2013 to December 2014, executive director, pipeline valuation and portfolio analysis from October 2011 to March 2014 and executive director, corporate planning and management reporting from 2005 to 2011. From January 2015 to October 2018, Mr. Lebowitz was retired. Mr. Lebowitz received a B.A. in Applied Mathematics and Economics from Brown University and an M.B.A. in Finance and International Business from Columbia Graduate School of Business.

How old is Joel Lebowitz?

Joel Lebowitz is 56, he's been the Executive Vice President e Chief Financial Officer of Schrodinger since 2018. There are 8 older and 13 younger executives at Schrodinger. The oldest executive at Schrodinger, Inc. is Dr. Richard A. Friesner, 68, who is the Co-Founder, Scientific Advisory Chairman and Director.

What's Joel Lebowitz's mailing address?

Joel's mailing address filed with the SEC is C/O SCHRODINGER, INC.,, 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK, NY, 10036.

Insiders trading at Schrodinger

Over the last 5 years, insiders at Schrodinger have traded over $1,009,056,149 worth of Schrodinger stock and bought 838,235 units worth $14,249,995 . The most active insiders traders include & Melinda Gates Foundation ..., David E Schrodinger Equity ..., eMichael Lynton. On average, Schrodinger executives and independent directors trade stock every 10 days with the average trade being worth of $2,459,207. The most recent stock trade was executed by Kenneth Patrick Lorton on 6 March 2024, trading 5,574 units of SDGR stock currently worth $24,191.

What does Schrodinger do?

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Complete history of Mr. Lebowitz stock trades at Schrodinger

Schrodinger executives and stock owners

Schrodinger executives and other stock owners filed with the SEC include:

• Dr. Ramy Farid Ph.D.,
  CEO, Pres & Director
• Yvonne Tran Esq.,
  Exec. VP, Chief Legal Officer & Sec.
• Dr. Karen Akinsanya Ph.D.,
  Exec. VP, Chief Biomedical Scientist and Head of Discovery R&D
• Ramy Farid,
  President, Chief Executive Officer, Director
• Cony D cruz,
  Executive Vice President - Chief Business Officer
• Yvonne Tran,
  Executive Vice President, Chief Legal Officer
• Dr. Richard A. Friesner,
  Co-Founder, Scientific Advisory Chairman and Director
• Richard Friesner,
  Independent Director
• Nancy Thornberry,
  Independent Director
• Gary Sender,
  Independent Director
• Rosana Kapeller-Libermann,
  Independent Director
• Timothy Wright,
  Independent Director
• Shane Brauner,
  Senior Vice President, Chief Information Officer
• Kenneth Lorton,
  Senior Vice President, Chief Technology Officer
• Karen Akinsanya,
  Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D
• Robert Abel,
  Executive Vice President - science
• Jorg Weiser,
  Executive Vice President, Managing Director
• Jennifer Daniel,
  Chief Human Resource Officer, Senior Vice President
• Joel Lebowitz,
  Executive Vice President, Chief Financial Officer
• Michael Lynton,
  Independent Chairman of the Board of Directors
• Michelle Byington,
  VP of HR
• Jennifer Mayer Daniel,
  Sr. VP & Chief HR Officer
• Jaren Irene Madden,
  Sr. VP of Investor Relations & Corp. Communications
• Shane Brauner,
  Exec. VP & Chief Information Officer
• Kenneth Patrick Lorton,
  Exec. VP & CTO
• Prof. William Goddard III,
  Co-Founder & Scientific Advisor
• Charles Ardai,
  10% owner
• Geoffrey Craig Porges,
  EVP & CFO
• David E Shaw,
  10% owner
• Gary L Ginsberg,
  Director
• Jeffrey Chodakewitz,
  Director
• & Melinda Gates Foundation ...,
  10% owner
• David E Schrodinger Equity ...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Jenny Herman,
  SVP & Controller
• Arun Oberoi,
  Director
• Margaret Dugan,
  Chief Medical Officer